Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. HIV infection is independently associated with a higher concentration of alpha-1 antitrypsin

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
OBJECTIVES: To investigate the interplay between resistance and adherence in the virological failure of three fundamentally different highly active antiretroviral therapy (HAART) regimens. METHODS: We retrospectively identified 56 verified primary virological failures (viral load >400 HIV-1 RNA copies/mL) among 293 patients randomized to two nucleoside reverse transcriptase inhibitors (NRTIs)+ritonavir+saquinavir (RS-arm) (n=115), two NRTIs+nevirapine+nelfinavir (NN-arm) (n=118), or abacavir+stavudine+didanosine (ASD-arm) (n=60) followed up for a median of 90 weeks. Data on adherence were collected from patient files, and genotyping was performed on plasma samples collected at time of failure. RESULTS: Treatment interruption or poor adherence was mainly caused by side effects and accounted for 74% of failures, and was associated with absence of resistance mutations. In the 30 failing patients not switched from randomized treatment, we found resistance in two of 12 patients in the RS-arm (M184 V only), four of six patients in the NN-arm [all four had non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations], and seven of 12 patients in the ASD-arm (NRTI mutations only). Two adherent patients on randomized treatment failed in the RS-arm, none in the NN-arm, and six in the ASD-arm. CONCLUSIONS: Primary virological failure was caused mainly by treatment interruption. No primary protease inhibitor (PI) mutations were found in patients failing on boosted saquinavir, whereas resistance to NNRTIs and NRTIs was prevalent in several patients failing on regimens based on these medications.
Original languageEnglish
JournalHIV Medicine
Volume5
Issue number5
Pages (from-to)344-51
Number of pages7
ISSN1464-2662
DOIs
Publication statusPublished - 2004

    Research areas

  • Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Drug Resistance, Multiple, Viral, Female, HIV Infections, HIV Protease Inhibitors, HIV-1, Humans, Male, Patient Compliance, Retrospective Studies, Reverse Transcriptase Inhibitors, Treatment Failure, Viral Load

ID: 32537020